Bradley E L, Reynhout J A, Peer G L
Department of Surgery, State University of New York (Buffalo), and Pain Management Services, Buffalo, NY, USA.
J Gastrointest Surg. 1998 Jan-Feb;2(1):88-94. doi: 10.1016/s1091-255x(98)80108-x.
Management of patients with intractable pain from "small duct" chronic pancreatitis has been difficult, often resulting in narcotic addiction and/or malnutrition from major pancreatic resection. Recently, denervation of sympathetic pain afferents from the pancreas by surgical splanchnicectomy has shown promise in relieving pain while preserving residual pancreatic function. However, results from surgical splanchnicectomy have been mixed in large part because of patient selection. Differentiating actual pancreatic pain from "pancreatic" pain caused by drug-seeking behavior, psychogenic diseases, or various somatically innervated conditions is clinically challenging at best. Between 1992 and 1996, twenty-two patients with 20 prior pancreatic operations, "small duct" chronic pancreatitis, and "pancreatic" pain requiring narcotics were evaluated. Each underwent differential epidural analgesia (DEA) using the following standard techniques: placebo, low-dose (sympathetic), and high-dose (somatic) blocks. Pain perceptions were recorded before and after DEA using a visual analogue scale (VAS). Six demonstrated a greater than 50% decrease in VAS pain after placebo injection and were eliminated from further study. In the remaining 16 patients, pain relief only occurred with sympathetic or somatic blockade. Greater and lesser splanchnicectomy (surgical splanchnicectomy) was performed 27 times in these 16 patients (11 bilateral, 6 synchronous) (5 unilateral; 2 right and 3 left) using thoracoscopic techniques in 14 patients and open thoracotomy in two. No significant surgical or anesthetic complications were encountered. Surgical splanchnicectomy resulted in an overall significant reduction in preoperative VAS scores (8.25 to 4.18; P <0.05). Ten of 13 patients with DEA-predicted sympathetic pain experienced a greater than 50% decrease in VAS after surgical splanchnicectomy, but only two had complete relief. None of the three patients with DEA-predicted somatic pain were benefited by splanchnicectomy. During an average follow-up of 23.3 months, initial good results from surgical splanchnicectomy were maintained in 8 of 10 patients. The following conclusions were reached: (1) surgical splanchnicectomy is a safe, often effective technique for amelioration of intractable pain from "small duct" chronic pancreatitis and (2) DEA is a promising approach for identifying patients most likely to respond to surgical splanchnicectomy.
“小导管”慢性胰腺炎所致顽固性疼痛患者的管理一直很困难,常因进行大的胰腺切除术而导致麻醉药物成瘾和/或营养不良。最近,通过手术内脏神经切除术去除胰腺的交感神经痛传入纤维,在缓解疼痛的同时保留残余胰腺功能方面显示出前景。然而,由于患者选择的原因,手术内脏神经切除术的结果好坏参半。区分真正的胰腺疼痛与由药物寻求行为、精神性疾病或各种躯体神经支配情况引起的“胰腺样”疼痛,在临床上充其量也具有挑战性。1992年至1996年期间,对22例曾接受过20次胰腺手术、患有“小导管”慢性胰腺炎且因“胰腺样”疼痛需要使用麻醉药物的患者进行了评估。每位患者均采用以下标准技术接受了鉴别性硬膜外镇痛(DEA):安慰剂、低剂量(交感神经)和高剂量(躯体)阻滞。使用视觉模拟量表(VAS)在DEA前后记录疼痛感受。6例患者在注射安慰剂后VAS疼痛评分下降超过50%,并被排除在进一步研究之外。在其余16例患者中,仅在交感神经或躯体阻滞时疼痛得到缓解。在这16例患者中,使用胸腔镜技术对14例患者和开放胸廓切开术对2例患者进行了27次大、小内脏神经切除术(手术内脏神经切除术)(11例双侧,6例同步)(5例单侧;2例右侧和3例左侧)。未遇到明显的手术或麻醉并发症。手术内脏神经切除术导致术前VAS评分总体显著降低(从8.25降至4.18;P<0.05)。13例经DEA预测为交感神经痛的患者中有10例在手术内脏神经切除术后VAS评分下降超过50%,但只有2例完全缓解。3例经DEA预测为躯体痛的患者均未从内脏神经切除术中获益。在平均23.3个月的随访期间,10例患者中有8例维持了手术内脏神经切除术最初的良好效果。得出以下结论:(1)手术内脏神经切除术是一种安全且通常有效的技术,可改善“小导管”慢性胰腺炎所致的顽固性疼痛;(2)DEA是一种有前景的方法,可用于识别最可能对手术内脏神经切除术有反应的患者。